Table 3.
Standard mean difference for the data before and after propensity score matching
| Variables | Before propensity score matching (n (%)) | After propensity score matching (n (%)) | ||||||
|---|---|---|---|---|---|---|---|---|
| PreORT group (n = 16,719) | PostORT group (n = 5360) | P | SMD | PreORT group (n = 16,719) | PostORT group (n = 5360) | P | SMD | |
| Sex | < 0.001 | 0.061 | 1.000 | < 0.001 | ||||
| Female | 6217.0 (37.2) | 2151.0 (40.1) | 1321.0 (36.0) | 1321.0 (36.0) | ||||
| Male | 10,502.0 (62.8) | 3209.0 (59.9) | 2346.0 (64.0) | 2346.0 (64.0) | ||||
| Age (y) | < 0.001 | 0.143 | 1.000 | < 0.001 | ||||
| 20–39 | 1061.0 (6.3) | 240.0 (4.5) | 115.0 (3.1) | 115.0 (3.1) | ||||
| 40–59 | 8387.0 (50.2) | 2435.0 (45.4) | 1780.0 (48.5) | 1780.0 (48.5) | ||||
| 60–79 | 7271.0 (43.5) | 2685.0 (50.1) | 1772.0 (48.3) | 1772.0 (48.3) | ||||
| Year of diagnosis | < 0.001 | 0.761 | 1.000 | < 0.001 | ||||
| 2000–2005 | 1762.0 (10.5) | 2014.0 (37.6) | 1097.0 (29.9) | 1097.0 (29.9) | ||||
| 2006–2010 | 3472.0 (20.8) | 1325.0 (24.7) | 959.0 (26.2) | 959.0 (26.2) | ||||
| 2011–2015 | 4967.0 (29.7) | 1059.0 (19.8) | 832.0 (22.7) | 832.0 (22.7) | ||||
| 2016–2021 | 6518.0 (39.0) | 962.0 (17.9) | 779.0 (21.2) | 779.0 (21.2) | ||||
| Race | 0.277 | 0.025 | 1.000 | < 0.001 | ||||
| White | 13,480.0 (80.6) | 4321.0 (80.6) | 3128.0 (85.3) | 3128.0 (85.3) | ||||
| Black | 1284.0 (7.7) | 441.0 (8.2) | 208.0 (5.7) | 208.0 (5.7) | ||||
| Other | 1955.0 (11.7) | 598.0 (11.2) | 331.0 (9.0) | 331.0 (9.0) | ||||
| Marital status | < 0.001 | 0.120 | 1.000 | < 0.001 | ||||
| Single | 3269.0 (19.6) | 808.0 (15.1) | 508.0 (13.9) | 508.0 (13.9) | ||||
| Married | 10,380.0 (62.1) | 3475.0 (64.8) | 2514.0 (68.6) | 2514.0 (68.6) | ||||
| Other | 3070.0 (18.4) | 1077.0 (20.1) | 645.0 (17.6) | 645.0 (17.6) | ||||
| Histologic type | < 0.001 | 0.067 | 1.000 | < 0.001 | ||||
| Adenocarcinoma | 15,790.0 (94.4) | 4991.0 (93.1) | 3542.0 (96.6) | 3542.0 (96.6) | ||||
| Mucous tumor | 804.0 (4.8) | 298.0 (5.6) | 116.0 (3.2) | 116.0 (3.2) | ||||
| Other | 125 (0.8) | 71 (1.3) | 9.0 (0.2) | 9.0 (0.2) | ||||
| Household income ($) | < 0.001 | 0.103 | ||||||
| 0–599,999 | 2883.0 (17.2) | 946.0 (17.6) | 628.0 (17.1) | 628.0 (17.1) | ||||
| 600,000–799,999 | 6155.0 (36.8) | 2211.0 (41.2) | 1521.0 (41.5) | 1521.0 (41.5) | ||||
| 800,000–999,999 | 5054.0 (30.2) | 1458.0 (27.2) | 1036.0 (28.3) | 1036.0 (28.3) | ||||
| > 1,000,000 | 2627.0 (15.7) | 745.0 (13.9) | 482.0 (13.1) | 482.0 (13.1) | ||||
| T stage | < 0.001 | 0.312 | NAN | < 0.001 | ||||
| T0 | 5.0 (0.0) | 1.0 (0.0) | 0.0 (0.0) | 0.0 (0.0) | ||||
| T1 | 216.0 (1.3) | 260.0 (4.9) | 82.0 (2.2) | 82.0 (2.2) | ||||
| T2 | 981.0 (5.9) | 639.0 (11.9) | 320.0 (8.7) | 320.0 (8.7) | ||||
| T3 | 13,444.0 (80.4) | 3936.0 (73.4) | 2993.0 (81.6) | 2993.0 (81.6) | ||||
| T4 | 2073.0 (12.4) | 524.0 (9.8) | 272.0 (7.4) | 272.0 (7.4) | ||||
| N stage | < 0.001 | 0.268 | 1.000 | < 0.001 | ||||
| T0 | 5964.0 (35.7) | 2001.0 (37.3) | 1501.0 (40.9) | 1501.0 (40.9) | ||||
| T1 | 8447.0 (50.5) | 2136.0 (39.9) | 1520.0 (41.5) | 1520.0 (41.5) | ||||
| T2 | 2308.0 (13.8) | 1223.0 (22.8) | 646.0 (17.6) | 646.0 (17.6) | ||||
| Chemotherapy | < 0.001 | 0.304 | ||||||
| No | 253.0 (1.5) | 422.0 (7.9) | 57.0 (1.6) | 57.0 (1.6) | ||||
| Yes | 16,466.0 (98.5) | 4938.0 (92.1) | 3610.0 (98.4) | 3610.0 (98.4) | ||||
| AJCC Stage | 0.029 | 0.034 | 1.000 | < 0.001 | ||||
| II | 5964.0 (35.7) | 2001.0 (37.3) | 1501.0 (40.9) | 1501.0 (40.9) | ||||
| III | 10,755.0 (64.3) | 3359.0 (62.7) | 2166.0 (59.1) | 2166.0 (59.1) | ||||
SMD, Standard mean difference; NAN, not a number; AJCC, American Joint Committee on Cancer
Bold indicates that P < 0.05